artemether/lumefantrine / Generic mfg. - LARVOL DELTA

OPTIMAH: OPTImizing Malaria And HIV Treatment in a Shifting Landscape in Africa (clinicaltrials.gov) - P4 | N=380 | Recruiting | Sponsor: Yale University | Not yet recruiting ➔ Recruiting

Enrollment open • Human Immunodeficiency Virus • Infectious Disease • Malaria

Persistent parasitaemia after artemether/lumefantrine for uncomplicated malaria revealing incidental filarial coinfection: a case report (ESCMID Global 2026) - No abstract available

Case report • Clinical • Infectious Disease • Malaria

Evaluation of Antimalarial Activity of Senna alata and Influence on Hepatic Caspase-3 and Nuclear Factor Keppa B. (PubMed, Parasite Immunol) - "Group 5 served as the standard drug control that received 20 mg/kg of LonartDS (artemether-lumefantrine)...Put together, the demonstrated antimalarial activity of EESa protected the liver from the inflammatory and apoptotic damages caused by malarial infection in experimental mice. This study supports the use of S. alata in the traditional treatment of malaria."

Journal • Hematological Disorders • Infectious Disease • Inflammation • Malaria • CASP3 • NFKB1

Pediatric Mixed Plasmodium vivax-P. falciparum Infection with Disparate Parasitemias: Diagnostic and Surveillance Challenges. (PubMed, Children (Basel)) - "Following confirmation of normal glucose-6-phosphate dehydrogenase activity, treatment with artemether-lumefantrine was initiated, followed by primaquine for hypnozoite eradication. It also underscores surveillance limitations that can misclassify mixed infections, potentially affecting epidemiological estimates and treatment strategies. Timely recognition and comprehensive diagnostic evaluation are essential to ensure appropriate antimalarial therapy, prevent complications, and inform public health interventions in regions where both species coexist."

Journal • Infectious Disease • Malaria • Pediatrics

The Effect of Artemether-Lumefantrine Combined with a Single Dose of Primaquine on Plasmodium falciparum Gametocyte Clearance and Post-Treatment Infectivity to Anopheles arabiensis. (PubMed, Trop Med Infect Dis) - "High baseline gametocyte density strongly correlated with increased infectivity. Adding SLD-PQ markedly accelerates gametocyte clearance and completely blocks post-treatment transmission. Submicroscopic gametocytemia contributed to residual transmission in the AL-only group. Incorporation of SLD-PQ alongside AL, in line with WHO recommendations, is advised to enhance post-treatment transmission blocking, with continued surveillance."

Journal • Infectious Disease • Malaria

Health Systems Implementation and Molecular Surveillance of Multiple First-Line Treatments for Uncomplicated Malaria in Western Kenya (clinicaltrials.gov) - P=N/A | N=316 | Completed | Sponsor: Strathmore University

New trial • Infectious Disease • Malaria

Therapeutic efficacy of dihydroartemisinin-piperaquine and artesunate-pyronaridine combinations in the treatment of uncomplicated Plasmodium falciparum malaria in Ghana, 2023. (PubMed, Front Public Health) - "Currently, artesunate-amodiaquine (AS-AQ), artemetherlumefantrine (AL), and artesunate-pyronaridine (AP) are the first-line medicines for treating uncomplicated malaria whilst dihydroartemisinin-piperaquine (DHAP) is the second-line medicine. We conclude that the therapeutic efficacy level of DHAP has remained high (>90%) since the baseline study in 2020/2021. Also, the baseline efficacy level of AP is high (>90%) warranting the use of both DHAP and AP in the treatment of uncomplicated malaria in the country."

Journal • Hematological Disorders • Infectious Disease • Malaria

Impact of Malaria Mass Drug Administration on Malaria Prevalence in Under 15 Children and Pregnant Women (clinicaltrials.gov) - P=N/A | N=3300 | Completed | Sponsor: Noguchi Memorial Institute for Medical Research

New trial • Infectious Disease • Malaria

Prevalence of antimalarial drug resistance molecular markers in Makenene, central Cameroon. (PubMed, Int J Parasitol Drugs Drug Resist) - "The in-depth analysis of genetic mutations associated with antimalarials resistance in this study, notably those with a high prevalence of mutations on the Pfdhfr and Pfdhps genes, highlights the immediate need for proactive strategies to combat resistance in Makenene. Continuous monitoring, including molecular and in vivo surveillance is crucial to uphold the effectiveness of current treatments and, more particularly, artemisinin-based combination therapies, and to enable better decision-making on effective treatment policy in Cameroon and in Africa as a whole."

Biomarker • Journal • Infectious Disease • Malaria • ABCB1

Spleen protective role, Antiplasmodial and Antioxidant activity of Polyalthia longifolia in mice infected with Plasmodium berghei parasite. (PubMed, Vet Anim Sci) - "Graded doses (100, 200 and 400 mg/kg/day) of ethanol extract of P. longifolia (EEPL) leaves and standard drug, Artemether and Lumefantrine (lonart) (2 mg/kg/day) were used for the treatment of malaria mice...In conclusion, EEPL treatment was able to control the macrophage response of mice erythrocytes infected with P. berghei. To pinpoint the exact mechanism causing these alterations, more research, such as characterizing the bioactive chemicals, might be required."

Journal • Preclinical • Infectious Disease • Malaria

Artemether-lumefantrine versus pyronaridine-artesunate for the treatment of malaria in patients with mild to moderate COVID-19 in Kenya and Burkina Faso: a randomised open-label trial (MALCOV). (PubMed, EClinicalMedicine) - P3 | "Several antimalarials exhibit antiviral activity against SARS-CoV-2 in vitro and have been suggested as potential therapeutic candidates for COVID-19, particularly pyronaridine-artesunate (PA), despite disappointing clinical results with chloroquine and hydroxychloroquine. Both treatments were highly effective as antimalarials and should continue to be considered first- or second-line treatment options for uncomplicated malaria in patients with mild to moderate COVID-19. Gates Foundation."

Journal • Infectious Disease • Malaria • Novel Coronavirus Disease • Respiratory Diseases

Treatment Failure and Post-Artesunate Delayed Haemolysis in a Returned Traveller From Uganda With Partially Drug-Resistant Severe Plasmodium falciparum Malaria. (PubMed, Med J Aust) - "He received intravenous artesunate followed by artemether-lumefantrine...Further testing for drug-resistant phenotypes and genotypes demonstrated reduced susceptibility to lumefantrine, an A675V mutation in the pfk13 gene and increased ring-stage survival, consistent with partial artemisinin resistance. The case highlights the high risk of P. falciparum treatment failure in patients with hyperparasitaemia and partial drug resistance."

Journal • Hematological Disorders • Infectious Disease • Malaria

Using sentinel surveillance system data to characterize severe malaria illness and quality of malaria case management among hospitalized patients in Kenya, 2017-2024. (PubMed, Malar J) - "Modifiable factors that suggested delayed care-seeking were associated with worse malaria outcomes in Kenya. Furthermore, gaps in diagnostic accuracy and adherence to treatment protocols for severe malaria were observed during chart review. These findings point to the importance of behaviour change strategies as well as messaging in the community that promote timely care-seeking, referrals and follow-up, especially for the youngest children. Potential malaria over-diagnosis underscores the need for strengthening quality assured microscopy programs with adequate training of microscopists and properly functioning microscopes and reagents, as well as an external quality assurance programme that routinely provide feedback on performance and identify areas for improvement."

Journal • Infectious Disease • Malaria

ALAQ: Pharmacokinetic Study of Artemether-lumefantrine and Amodiaquine in Healthy Subjects (clinicaltrials.gov) - P1 | N=8 | Terminated | Sponsor: University of Oxford | N=16 ➔ 8 | Trial completion date: Aug 2026 ➔ Apr 2025 | Recruiting ➔ Terminated | Trial primary completion date: Aug 2026 ➔ Apr 2025; The decision was made due to the expired investigational drug and regulatory changes by the Thai FDA, along with increased importation costs. The research team and investigational drug sponsor agreed to seek approval for early project termination.

Enrollment change • Trial completion date • Trial primary completion date • Trial termination

Prescription-only medicine requests by clients: Insights from community pharmacies. (PubMed, Explor Res Clin Soc Pharm) - "Artemether/lumefantrine and amoxicillin/clavulanate were the most sought medicines. Strengthen national prescribing policies by granting pharmacists structured prescribing authority, thereby promoting accountability and the rational use of medicines."

Journal • Pain • Women's Health

Mapping the prevalence of molecular markers of Plasmodium falciparum artemisinin partial resistance in Africa: a spatial-temporal modelling study. (PubMed, medRxiv) - "Partner drug amodiaquine marker mdr1 86Y is fading, but crt 76T remains prevalent in the Horn of Africa. This suggests the need to more broadly shift away from reliance on artemether-lumefantrine and necessitates greater molecular surveillance in sub-Saharan Africa, prioritizing the identified high-prevalence regions (Uganda, Rwanda, Ethiopia, Eritrea) and neighboring countries. Our integrated approach provides the foundational, evidence-based tools needed by national malaria control programs (NMCPs) and the WHO to refine drug policy decisions before ART-R develops into clinical treatment failure."

Biomarker • Journal • Infectious Disease • Malaria • ABCB1

Therapeutic efficacy of artemether-lumefantrine and molecular markers of antimalarial resistance in Niger, 2022. (PubMed, Malar J) - "In all four sites evaluated, AL retains therapeutic efficacies above the 90% WHO-recommended threshold using the primary three-out-of-three match criteria. In Aguié and Baban Tabki, efficacy remained above the threshold with certain match criteria and statistical approaches but fell below the cutoff using two-out-of-three matching and per-protocol methods, suggesting emerging efficacy concerns in southern parts of the country."

Biomarker • Journal • Infectious Disease • Malaria

Artemisinin-Based Combination Therapies in East Africa: A Systematic Review of Quality, Clinical Efficacy, and Regulatory Progress Towards Sustainable Malaria Control. (PubMed, Trop Med Int Health) - "The findings of this study revealed that 11.2% of ACTs samples were found to be poor quality. The clinical data reflects that in East Africa, ACTs remain effective despite the prevalence of substandard and falsified ACTs and emerging resistance threatening long-term gains. Thus, strengthening regional regulatory harmonization, pharmacovigilance, molecular surveillance, and local manufacturing capacity is essential to combat resistance of ACT and ensure equitable access to quality-assured therapies."

Journal • Review • Infectious Disease • Malaria

Locally Acquired Plasmodium falciparum Malaria in a Non-endemic Region of Lebanon: A Case Report. (PubMed, Cureus) - "Given the patient's age and high parasitemia, she was treated with intravenous artesunate, followed by oral artemether-lumefantrine, and subsequently made a full recovery. The absence of conventional exposure routes, such as travel, blood transfusion, or organ transplant, makes this case a significant diagnostic and public health challenge. This case highlights the need for sustained malaria surveillance and heightened awareness among clinicians in historically non-endemic areas."

Journal • Hematological Disorders • Infectious Disease • Leukopenia • Malaria • Pain • Thrombocytopenia • Transplantation

KALUMA: Efficacy, Safety and Tolerability of KLU156 in Adults and Children With Uncomplicated P. Falciparum Malaria (clinicaltrials.gov) - P3 | N=1720 | Completed | Sponsor: Novartis Pharmaceuticals | Active, not recruiting ➔ Completed | Trial completion date: Aug 2027 ➔ Nov 2025

Trial completion • Trial completion date • Infectious Disease • Malaria

Comparative molecular surveillance of polymorphisms in chloroquine resistance transporter, multidrug resistance 1, and Kelch 13 genes associated with antimalarial drug resistance in Plasmodium falciparum isolates from Western Kenya. (PubMed, Malar J) - "Our findings reveal the persistence of the Pfcrt CVIET haplotype and elevated Pfk13 A675V mutation in Kisii, with a moderate prevalence of Pfmdr1 Y184F mutation in both regions. Crucially, we detected emerging novel Pfmdr1 N146I and rare Pfk13 S522C and R561H mutations in Kisumu. Given that artemether-lumefantrine is Kenya's first-line treatment, continuous molecular surveillance is essential to elucidate the selection pressures driving the spread of resistant P. falciparum in western Kenya."

Journal • Infectious Disease • Malaria • ABCB1

Pharmacokinetics and Pharmacodynamics of the Gametocytocidal and Post-treatment Chemoprotective Effects of Antimalarials (clinicaltrials.gov) - P2/3 | N=182 | Active, not recruiting | Sponsor: Johns Hopkins Bloomberg School of Public Health | Trial completion date: Dec 2025 ➔ Dec 2026

Trial completion date • Infectious Disease • Malaria

Delayed Hemolytic Anemia After Artemether-Lumefantrine in Plasmodium falciparum Malaria: A Case Report. (PubMed, Int J Infect Dis) - "We report a case of DHA following an extended course of oral artemether-lumefantrine (AL) in a 50-year-old male with follicular lymphoma treated with rituximab 10 months ago and severe Plasmodium falciparum malaria (parasitemia >10%). The positive Coombs test suggests a possible immune-mediated component, differentiating it from the typical non-immune mechanism. This case highlights that DHA can occur after oral AL, not just intravenous artesunate, and underscores the critical need for vigilant post-treatment monitoring (2-4 weeks) of hemoglobin in high-risk patients with comorbidities or high parasite burdens."

Journal • Anemia • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Malaria • Oncology

To evaluate efficacy, safety, tolerability and PK of intravenous cipargamin in participants with severe Plasmodium falciparum (clinicaltrialsregister.eu) - P2 | N=254 | Sponsor: Novartis Pharma AG

New P2 trial • Infectious Disease • Malaria • Pediatrics

Barriers and facilitators to the adoption of multiple first-line therapies for management of uncomplicated malaria in Tanzania: a multi-method qualitative study. (PubMed, Malar J) - "MFT presents a promising strategy for prolonging ACT efficacy and enhancing malaria case management in Tanzania. However, financial constraints, import dependence on ALU, and inadequate provider preparedness limit implementation. Successful adoption will require diversification of ACT imports, strengthening supply chains, sustained capacity-building, and embedding surveillance and regulatory data into policy decision-making."

Journal • Infectious Disease • Malaria